Opus Genetics, Inc.
IRD
$3.61
-$0.11-2.96%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -36.09% | -12.22% | 29.15% | 74.60% | -6.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.09% | -12.22% | 29.15% | 74.60% | -6.25% |
| Cost of Revenue | 28.97% | 10.95% | 14.05% | 14.96% | 63.88% |
| Gross Profit | -98.78% | -30.35% | -3.57% | 17.72% | -730.64% |
| SG&A Expenses | -2.04% | 8.95% | 21.72% | 73.43% | 68.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.62% | 10.15% | 17.15% | 36.86% | 65.87% |
| Operating Income | -37.25% | -18.57% | -13.28% | -26.13% | -144.53% |
| Income Before Tax | -84.66% | -82.42% | 13.80% | -150.80% | -313.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.66% | -82.42% | 13.80% | -150.82% | -313.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.66% | -82.42% | 13.80% | -150.82% | -313.15% |
| EBIT | -37.25% | -18.57% | -13.28% | -26.13% | -144.53% |
| EBITDA | -37.22% | -18.48% | -13.15% | -26.02% | -144.44% |
| EPS Basic | 28.44% | 33.42% | 60.16% | -62.23% | -234.28% |
| Normalized Basic EPS | -46.42% | -24.23% | 27.14% | 22.61% | -63.63% |
| EPS Diluted | 25.55% | 33.27% | 60.02% | -62.50% | -229.14% |
| Normalized Diluted EPS | -45.04% | -24.23% | 27.14% | 22.61% | -60.30% |
| Average Basic Shares Outstanding | 116.95% | 159.42% | 132.55% | 99.28% | 62.22% |
| Average Diluted Shares Outstanding | 127.29% | 159.42% | 132.55% | 99.28% | 60.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |